CYTOKINETICS INC 4

Robert I. Blum (President & CEO of Cytokinetics, Inc.) exercised 7,500 stock options at $10.60 and sold 7,500 common shares at $76.76 on August 10, 2026.

On August 10, 2026, Robert I. Blum, President & CEO of Cytokinetics, Inc., exercised 7,500 non-qualified stock options at an exercise price of $10.60 per share into common stock and on the same day sold the resulting 7,500 shares at $76.76 per share in an apparent cashless or sell-to-cover type transaction. The option exercise added 7,500 shares of common stock at a cost basis of $10.60, increasing his directly held common stock position to 385,320 shares before the sale; the subsequent sale reduced his direct holdings to 377,820 shares. The gross value of shares sold was approximately $575,700, implying a gain of roughly $495,300 over the exercise price, while he continues to hold additional shares indirectly through two irrevocable trusts (each holding 2,083 shares), which are disclosed as indirect beneficial ownership. Overall, this Form 4 reflects routine executive option exercise activity paired with a market sale, without a net increase in total shares outstanding from the insider’s perspective.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000087

Alert Tier

6